# PRODUCT INFORMATION



# CCG-232601

Item No. 24382

CAS Registry No.: 1922099-21-5

Formal Name: N-(4-chlorophenyl)-5,5-difluoro-

1-[3-(4-pyridinyl)benzoyl]-3-

piperidinecarboxamide

MF:  $C_{24}H_{20}CIF_2N_3O_2$ 

455.9 FW: **Purity:** ≥98% UV/Vis.:  $\lambda_{\text{max}}$ : 250 nm Supplied as: A crystalline solid

Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## **Laboratory Procedures**

CCG-232601 is supplied as a crystalline solid. A stock solution may be made by dissolving the CCG-232601 in the solvent of choice, which should be purged with an inert gas. CCG-232601 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of CCG-232601 in these solvents is approximately 30 mg/ml.

CCG-232601 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CCG-232601 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. CCG-232601 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

## Description

CCG-232601 is an inhibitor of the Rho/MRTF/SRF transcriptional pathway and a derivative of CCG-203971 (Item No.15075).1 CCG-232601 inhibits MRTF-dependent transcription in HEK293T cells  $(IC_{50} = 0.55 \,\mu\text{M})$  in a luciferase reporter assay). It also reduces expression of  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA) in  $TGF-\beta$ -stimulated human dermal fibroblasts to 31% of control when used at a concentration of 10  $\mu$ M. CCG-232601 (50 mg/kg) inhibits increases in dermal thickness and hydroxyproline content in a mouse model of dermal fibrosis induced by bleomycin (Item No. 13877).

#### Reference

1. Hutchings, K.M., Lisabeth, E.M., Rajeswaran, W., et al. Pharmacokinetic optimization [sic] of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. Bioorg. Med. Chem. Lett. 27(8), 1744-1749 (2017).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

# WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the mater can be found on our website.

Copyright Cayman Chemical Company, 12/15/2022

## **CAYMAN CHEMICAL**

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM